For clinics, labs & institutional partners
Precision oncology, backed by data. Focused on outcomes.
The combination of advanced omics analyses and artificial intelligence brings measurable improvement in personalized cancer treatment.
The evidence for genomically guided treatment
Large clinical studies show that approximately 38% of patients undergoing DNA sequencing (NGS) have findings that can lead to targeted therapy. In randomized data, tumour response with genomically guided treatment reached 17.5% vs. 10% with standard therapy, and after one year, 22% of patients remained progression-free vs. 8.3%.
Expanding analysis to RNA and other omics approaches increases the chance of clinical benefit to 26% of patients. When functional drug testing is added, improvement in disease progression is seen in 50% of patients compared to their previous treatment.
Moreover, when treatment decisions are guided by a molecular tumour board, the risk of disease worsening decreases by 35–50%—confirming that the more precisely therapy is tailored, the higher the likelihood of success.
What we offer
We provide a fully integrated precision oncology platform that transforms complex biological data into clear, actionable treatment strategies for clinicians and partners.
Comprehensive multi-omics profiling
We go beyond standard diagnostics to build a complete molecular picture of each tumour:
- NGS DNA sequencing to identify actionable mutations
- RNA / transcriptomics to understand gene expression and pathway activation
- Proteomics & phosphoproteomics to reveal functional signalling and drug targets
This layered approach captures not just what mutations exist, but how the tumour behaves.
Functional drug sensitivity testing (ex vivo)
We test real patient tumour cells against multiple therapies:
- Identify which drugs actually work on the tumour
- Detect resistance early
- Support selection of the most effective therapy before treatment begins
This bridges the gap between theoretical targets and real biological response.
AI-Driven Interpretation
Our bioinformatics and AI platforms:
- Compare patient data against millions of data points and clinical cases
- Predict therapy response and resistance
- Identify targeted therapies, immunotherapy options, and clinical trials
The result is a clear, structured report—translating complexity into clinical decision support.
Molecular tumour board
Every case is reviewed by a multidisciplinary expert panel:
- Oncologists, molecular biologists, and bioinformaticians
- Evidence-based treatment prioritization
- Personalized recommendations aligned with current guidelines and emerging science
This ensures that data is not only analysed—but correctly interpreted and clinically applied.
End-to-end delivery for partners
We don't just perform advanced analyses—we fully manage and deliver them as a seamless service for our partners.
- We coordinate and cover the complete analytical workflow (from sample processing to multi-omics analysis)
- We integrate all findings into a clinically validated, easy-to-use report
- We provide clear, actionable results that physicians can confidently use in decision-making
For our partners, this means you can offer cutting-edge precision oncology without building the infrastructure yourself—while delivering highly reliable and clinically relevant outputs to your clients and patients.
Beyond oncology: Early risk & prevention
OmixMe analysis are not limited to patients already diagnosed with cancer. We also support proactive health management by identifying early predispositions:
- Genetic risk profiling for cancer susceptibility
- Identification of predispositions to chronic diseases (e.g., metabolic, cardiovascular, neurodegenerative)
- Insights for preventive care and early intervention strategies
- Personalized recommendations to support long-term health management
This allows partners to expand their offering from treatment-focused services to preventive, predictive, and personalized healthcare.
Real cells. Real drugs. Real response.
Functional ex vivo testing on patient tumour cells helps identify which therapies actually work — and detects resistance before treatment begins.
Every case, reviewed by an expert panel.
Oncologists, molecular biologists and bioinformaticians turn raw data into evidence-based, personalized recommendations aligned with current guidelines.
How we change the treatment pathway
Traditional oncology often relies on generalized protocols and trial-and-error. Our approach replaces this with data-driven precision:
We provide clinicians with analysis - toward the highest probability of success.
Value for partners
By cooperating with us, partners gain:
Higher treatment precision and improved patient outcomes
Faster therapy selection with reduced trial-and-error
Access to advanced diagnostics and AI interpretation
Improved clinical trial matching and eligibility
Expansion into preventive and personalized health services
Differentiation through cutting-edge precision medicine solutions
Real impact
Personalized oncology is not just about extending survival—it improves quality of life:
- Higher response rates when actionable targets are identified
- Reduced toxicity through targeted therapies
- Longer progression-free survival
- Potential to manage cancer as a chronic condition
Our approach enables clinicians to stay ahead of disease progression, act earlier, and choose smarter.
A New Standard in Oncology
We combine:
Multi-omics profiling + functional testing + AI interpretation + expert review
→ into one unified solution that supports better decisions, better treatments, and better outcomes.
Partner with OmixMe
Tell us about your clinic, lab or institution and we'll get back with the right next step.